Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
angiopoietin-primed autologous peripheral blood stem cells
- Development stage
- Phase 3
- Lead developer
- Seoul National University Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial
01
Overview
**Angiopoietin-primed autologous peripheral blood stem cells** are an investigational autologous cell therapy being evaluated for acute myocardial infarction in the MAGIC-CELL-6-PRIMING study. Peripheral blood stem cells are mobilized with granulocyte colony-stimulating factor and erythropoietin, collected by apheresis, then primed ex vivo for one hour with the engineered angiopoietin-1 variant FVA3-Ang1 before intracoronary administration. Angiopoietin-1 priming activates Tie2 signaling and promotes Ets-1-associated endothelial-lineage commitment and adhesion-program induction, including increased integrin alpha4 beta1 and alpha5 beta1 expression, with the goal of improving vascular engraftment, angiogenesis, and myocardial repair after infarction. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12738441/))
- Other names
- FVA3-Ang1-primed mobilized peripheral blood stem cellsFVA-3-Ang1-primed mobilized peripheral blood stem cellsFVA 3-Ang1-primed mobilized peripheral blood stem cellsFVA3-Ang1-primed mobPBSCsFVA-3-Ang1-primed mobPBSCsFVA 3-Ang1-primed mobPBSCs
02
Targets
TEK (Tie2)
Beyond the preview
Go deeper on angiopoietin-primed autologous peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on angiopoietin-primed autologous peripheral blood stem cells.